Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490458 | 0.88 | HSD17B10 (0.55) | ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL22867617 | 0.87 | CYP4F2 (0.51) | POLBALDH1A1CYP4F2CYP4A11NPC1 | |
| SCHEMBL585472 | 0.86 | APLNR (0.56) | POLBALDH1A1NPC1PKMRAB9A | |
| SCHEMBL432804 | 0.85 | CYP4F2 (0.50) | POLBALDH1A1TDP1TSHRCYP4F2 | |
| SCHEMBL434775 | 0.85 | POLB (0.52) | POLBALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL1549816 | 0.85 | CYP4F2 (0.50) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL6035972 | 0.85 | POLB (0.68) | POLBTSHRCYP4F2CYP4A11NPC1 | |
| SCHEMBL21455751 | 0.85 | ALDH1A1 (0.53) | POLBALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL30482840 | 0.85 | ALDH1A1 (0.53) | POLBALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL17722574 | 0.84 | CYP4F2 (0.54) | ALDH1A1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-5124478-A | ACID-LABILE ANCHOR GROUPS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY A SOLID-PHASE METHOD | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | POLB 259/4885ALDH1A1 181/4885TDP1 1049/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | POLB 236/4885ALDH1A1 314/4885TDP1 2793/4885 |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | POLB 3400/4885ALDH1A1 886/4885TDP1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.